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It is known that narcotic antagonists interact with many cholinergic pathways but less in known about spe- 
cific mechanisms. Using neonatal rat myoballs to study single channel behaviour of the acetylcholinegated 
nicotinic receptor, it was found that micromolar concentrations of naltrexone had no effect on channel con- 
ductance but caused open channel blockade by increasing the flickering from the open to the closed state 
in a concentration-dependent manner. At micromolar concentrations of naltrexone, the frequency of chan- 
nel opening was decreased and bursts were grouped in clusters, whereas at nanomolar levels the frequency 
of opening was increased. The sequential model for ion-channel blockade cannot explain these effects, and 
an alternative allosteric mechanism of action is proposed. 
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1. INTRODUCTION 
The narcotic antagonists naloxone and naltrex- 
one have potent and stereoselective ffects on 
opiate receptors, and in addition, they may also in- 
teract with other receptors and neurotransmitter 
pathways [1.21. In cholinergic systems, a variety of 
in vitro, in vivo and behavioural experiments have 
demonstrated that both muscarinic and nicotinic 
pathways can be affected by narcotic agonists and 
antagonists [3-91. Although some of these interac- 
tions may not be at the postsynaptic receptor, there 
is electrophysiological evidence that naltrexone has 
a direct effect on the nicotinic receptor of the 
motor endplate [ 10,111. Oliveira and Albuquerque 
[lo] used a two microelectrode voltage clamp to 
record endplate currents (EPCs) and miniature 
endplate currents at the frog neuromuscular junc- 
tion and suggested that naltrexone interacts with 
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both the open and closed form of the receptor. 
Similarly, Argentieri and McArdle [I 1] studied 
EPCs of rat muscle and concluded that naltrexone 
blocks open channels in a manner similar to that of 
many local anesthetics. 
The aim of the present study was to gain detailed 
information on the reaction between an opiate 
agent and the nicotinic receptor using the method 
of single channel recording [12]. With this tech- 
nique it is possible to study the interaction of 
various agonists and antagonists on individual 
receptor molecules, thus allowing closer scrutiny 
and testing of possible mechanisms. 
2. MATERIALS AND METHODS 
Genera1 details of the experimental protocol and 
data analysis have been previousfy described [ 131. 
Briefly, nicotinic receptors on cultured rat myoballs 
were studied in Hanks solution at 10°C (pH 7.2). 
Cells were viewed with Hoffman interference op- 
tics on an inverted microscope (Nikon), and 
mechanical vibrations were minimized with a 
pneumatically isolated table (Kinetic Systems). 
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Patch pipettes (2 MO) were made from alumino- 
silicate glass (A-M Systems), fire-polished, and 
used without silicone coating. When seals were 
greater than 2-5 Gfi, single channel data under 
voltage clamp (List Electronic, L/M-EPC-5) were 
collected on a 4 channel FM tape recorder (Racal) 
at 1 kHz bandwidth for subsequent analysis. 
Acetylcholine (ACh) concentration used to ac- 
tivate the receptors was 0.2 PM and all solutions 
contained 0.3 PM tetrodotoxin (Sigma) to inhibit 
sodium channels. Recording modes were inside- 
out, and perfused outside-out using a micro- 
chamber [14]. With outside-out patches, Ca’+ was 
not added to the Hanks solution in the pipette. FM 
tape recordings of data were digitized at 5 kHz and 
analyzed using an automated computer procedure 
[ 131 which generated histograms of current ampli- 
tude and estimated open, shut and burst lifetimes; 
for the purposes of this study, bursts were defined 
as a sequence of openings separated by closures of 
not greater than 8 ms. Data passing through the 
50% point of channel conductance were taken to 
indicate a change of state for channels opening and 
closing. (-)-Naltrexone was supplied by Endo 
Laboratories. 
3. RESULTS 
Naltrexone (0.2-30 PM) had no effect on single 
channel conductance (linear regression of conduc- 
tance (7) on naltrexone concentration from O-10 
PM gave an intercept of 21.4kO.51 pS (SE) and a 
slope of - 0.094 + 0.091 for n = 11). However, in a 
concentration-dependent manner it both decreased 
mean open channel lifetime (fig.1) and caused 
openings to be grouped into clusters separated by 
silent periods of several seconds duration (fig.2). 
The decrease in mean channel open time was 
brought about by increased flickering during the 
open state, similar to that seen with the local 
anesthetic agents QX222 and QX3 14 [15]. This ef- 
fect of decreased open lifetime through increased 
flickering was reflected in the number of openings 
per burst, with an average 2-fold increase for 30 
PM naltrexone compared to control. Frequency 
histograms of closed times also illustrated this 
behaviour; fig.3 shows data from one inside-out 
patch where in the presence of ACh alone, flicker- 
ing was minimal with 9% of closed times being less 
than 8 ms, while in another patch with 5 PM 
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Fig.1. Frequency histograms showing the number of 
open channel events falling within incremental 1 ms 
bins. Data from two inside-out patches with a trans- 
membrane potential (VH) of - 40 mV (pipette held at 
+40 mV with respect to bath). (A) Control in the 
presence of 0.2 FM ACh, 249 open channels counted, 
mean open channel lifetime (rope,,) = 8.3 ms estimated 
by log-linear regression, r = 0.96. Excess number of 
brief openings in the first 1.4 ms excluded. (B) 0.2 pM 
ACh in the presence of 10 pM naltrexone, 177 channels. 
counted, rope” = 4.9 ms, r = 0.95, data in the first 0.2 
ms excluded. 
naltrexone present, such closures represented 33% 
of the total. Naltrexone at concentrations above 5 
PM also had a time-dependent effect on decreasing 
the frequency of channel opening, generally taking 
several minutes to achieve equilibrium. The time 
taken to reach equilibrium decreased with increas- 
ing concentration. 
In contrast to these blocking effects seen most 
clearly at naltrexone concentrations in the micro- 
molar range, it was noticed that 0.2pM naltrexone 
increased the frequency of channel opening, and 
that this effect took some minutes to reach a max- 
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Fig.2. Frequency of channel opening as a function of 
time for two inside-out patches, VH = -60 mV. (A) 
Control, 0.2 ,uM ACh, total of 63 openings showing 
relatively regular behaviour. (B) 0.2 PM ACh in the 
presence of 30pM naltrexone, total of 116 openings, il- 
lustrating grouping into clusters separated by quiescent 
periods of several seconds duration. 
imum following exposure and seal formation. This 
stimulatory effect was confirmed in a separate per- 
fused outside-out preparation where the same 
patch was sequentially exposed to 0.2 ,uM ACh, 
0.25 PM naltrexone and then the two agents 
together. Fig.4 shows that 0.25 PM naltrexone had 
no intrinsic agonist activity at the nicotinic recep- 
tor, whereas when combined with 0.2 yM ACh 
there was an increase in channel opening activity 
compared to ACh alone, manifesting in many in- 
stances as double and triple concurrent openings. 
Mean open lifetime was reduced from 7.3 to 5.2 ms 
and average openings/burst increased from 1.4 to 
2.0 for ACh alone and ACh plus 0.25 PM naltrex- 
one, respectively. The frequency of channel open- 
ing in the presence of both agents immediately 
following exposure was 4 times greater than in the 
control situation, and this ratio increased to 6-fold 
within 2 min. In this recording mode, as with the 
inside-out patch experiments, there was no effect 
of naltrexone on single channel conductance. 
4. DISCUSSION 
This study reports various effects of naltrexone 
on normal ACh activation of the nicotinic recep- 
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Fig.3. Closed time histograms in the absence (A) and 
presence (B) of 5 pM naltrexone. Separate inside-out 
patches, ACh concentration in both was 0.2 PM, vn = 
- 60 mV. In (A) 9% of closed times were less than 8 ms 
while in (B) such closures were 33% of the total. 
tor, namely: (i) a concentration-dependent i crease 
in flickering of open channels to the closed state, 
leading to a progressive decrease in mean open 
channel ifetime and increased number of openings 
per burst; (ii) a time- and concentration-dependent 
decrease in frequency of channel opening, with 
burst of openings grouped into clusters; and (iii) at 
nanomolar concentrations, an increase in the fre- 
quency of channel opening. Considering the 
literature documenting non-opiate effects of the 
narcotic antagonists, it is not surprising that 
naltrexone interacts directly with the nicotinic 
receptor. However, the potency, with demonstrable 
effects even in the nanomolar concentration range, 
was unexpected. This phenomenon reinforces the 
statements of others [1,2] that demonstration of 
change in some biological response following ad- 
ministration of narcotic antagonists should be 
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Fig.4. Single channel records from the same perfused patch showing the excitatory effect of naltrexone. Data were 
recorded at 1 kHz bandwidth, temperature lO”C, VH = - 40 mV. (A) 0.2 PM ACh; (B) 0.25 pM naltrexone; (C) 0.2 
,uM ACh plus 0.25 ,uM naltrexone. Downward deflections represent positive inward current. 
regarded as necessary but not sufficient evidence 
for proof of an opioid pathway in the response. 
At concentrations in the micromolar range, 
naltrexone has effects very similar to those agents 
which produce a non-competitive blockade of the 
open ion channel, and which have commonly been 
interpreted in terms of a sequential blocking model 
(e.g., procaine [ 161, atropine [ 171 and bupivacaine 
1181). The general applicability of this model has 
been questioned [19-221 and here, a sequential 
block model would not directly explain the ob- 
served naltrexone closed channel blockade and 
clustering behaviour reminiscent of agonist- 
induced desensitization, nor would it predict the 
concentration-dependent biphasic effect, with ac- 
tivation at low levels followed by blockade at 
higher levels. 
We favour an allosteric model to describe the 
multiple effects of naltrexone at the nicotinic 
receptor as follows: 
2A+R 
A 
kZ A2R 
+ AzR* * AzDi 
where A = ACh, R = receptor, A2R* = open 
form of the receptor, and A2Di = various desen- 
sitized forms of the receptor, and kl, k2, cy, ,& = 
binding and isomerization rate constants. The 
observations and interpretations at low naltrexone 
concentrations (where clustering and presumably 
desensitization were minimal) are that firstly, 
naltrexone shortens channel open time and so has 
the principal effect of increasing LY, and secondly, 
the average number of openings per burst is in- 
creased, which implies that the ratio P/k2 is in- 
creased [23]. It is possible that nanomolar concen- 
trations of naltrexone affect only the isomerization 
rate constants a and ,B in the scheme above, in- 
creasing both. Alternatively, naltrexone could 
23 
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stabilize the biliganded but closed species (AlR), 
since this would also increase openings and open- 
ings per burst by shifting the binding equilibrium 
to the right. Higher concentrations of naltrexone 
would seem to shift the equilibrium between open 
channels (A2R) and the various inactivated forms 
(AzDi) in favour of the latter, while continuing to 
also increase a. The potency of the effect on open- 
ings per burst suggests a specific interaction be- 
tween naltrexone and the receptor where only a 
single molecule of naltrexone may be bound. The 
further graded change in open channel lifetime and 
bursting behaviour with increasing naltrexone con- 
centration suggests additional lower affinity sites 
which may be located elsewhere on the receptor, or 
could involve the lipid membrane phase [24]. The 
finding that many of the effects of naltrexone did 
not reach equilibrium for some minutes suggests 
restricted site access such as would occur if they 
were located near or in the lipid phase. 
A number of studies provide supporting evidence 
that the interaction of naltrexone with the nicotinic 
receptor, at least at lower concentrations, is pro- 
bably specific. Recent sequencing of the four 
subunit forms of the receptor has shown that the 
hydrophobic and putative ACh binding sites in the 
cy subunits are highly conserved in the other three 
forms [25], and hence one might expect at least 
three non-agonist recognition sites where drug 
molecules could bind. It has also been suggested 
that there is a high affinity allosteric site for the 
noncompetitive channel blockers, probably located 
within the ion channel itself [24]. Furthermore, 
from experiments on the nicotinic receptor of a 
clonal muscle cell line it has been found that dibu- 
Caine, QX314 and histrionicotoxin act by similar 
allosteric mechanisms in binding to at least two 
sites per receptor molecule, causing increased 
agonist affinity and desensitization [26]. 
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